Assembly Biosciences Inc
NASDAQ:ASMB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Assembly Biosciences Inc
NASDAQ:ASMB
|
US |
|
H
|
Hui Lyu Ecological Technology Groups Co Ltd
SZSE:001267
|
CN |
|
Becker Milk Co Ltd
TSX:BEK.B
|
CA |
|
S
|
Shandong Longertek Technology Co Ltd
SZSE:300594
|
CN |
|
M
|
Minmetals Capital Co Ltd
SSE:600390
|
CN |
|
Ocean One Holding Ltd
HKEX:8476
|
HK |
|
I
|
Inmobiliaria San Patricio SA
SGO:ISANPA
|
CL |
|
H
|
Henan Senyuan Electric Co Ltd
SZSE:002358
|
CN |
|
K
|
KAISA JiaYun Technology Inc
SZSE:300242
|
CN |
Assembly Biosciences Inc
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 102 full-time employees. The company went IPO on 2010-12-17. The firm is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The firm is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 102 full-time employees. The company went IPO on 2010-12-17. The firm is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The firm is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.
